KR101668849B1 - 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도 - Google Patents

모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도 Download PDF

Info

Publication number
KR101668849B1
KR101668849B1 KR1020107018777A KR20107018777A KR101668849B1 KR 101668849 B1 KR101668849 B1 KR 101668849B1 KR 1020107018777 A KR1020107018777 A KR 1020107018777A KR 20107018777 A KR20107018777 A KR 20107018777A KR 101668849 B1 KR101668849 B1 KR 101668849B1
Authority
KR
South Korea
Prior art keywords
virus
veev
alphavirus
ires
attenuated recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107018777A
Other languages
English (en)
Korean (ko)
Other versions
KR20100106599A (ko
Inventor
스캇 씨 위버
일리야 브이 프롤로프
엘레나 프로로바
Original Assignee
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 filed Critical 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템
Publication of KR20100106599A publication Critical patent/KR20100106599A/ko
Application granted granted Critical
Publication of KR101668849B1 publication Critical patent/KR101668849B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020107018777A 2008-01-24 2009-01-23 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도 Expired - Fee Related KR101668849B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6222908P 2008-01-24 2008-01-24
US61/062,229 2008-01-24
PCT/US2009/000458 WO2009131604A2 (en) 2008-01-24 2009-01-23 Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167029024A Division KR101913790B1 (ko) 2008-01-24 2009-01-23 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20100106599A KR20100106599A (ko) 2010-10-01
KR101668849B1 true KR101668849B1 (ko) 2016-10-24

Family

ID=41217313

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107018777A Expired - Fee Related KR101668849B1 (ko) 2008-01-24 2009-01-23 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도
KR1020167029024A Expired - Fee Related KR101913790B1 (ko) 2008-01-24 2009-01-23 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167029024A Expired - Fee Related KR101913790B1 (ko) 2008-01-24 2009-01-23 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도

Country Status (15)

Country Link
US (3) US8426188B2 (https=)
EP (2) EP2250269B1 (https=)
JP (1) JP5758632B2 (https=)
KR (2) KR101668849B1 (https=)
CN (1) CN102083986B (https=)
AU (1) AU2009238667A1 (https=)
CA (2) CA2910235C (https=)
CO (1) CO6290702A2 (https=)
IL (2) IL207167A (https=)
MX (3) MX367792B (https=)
MY (1) MY178870A (https=)
NZ (2) NZ603790A (https=)
SG (2) SG187513A1 (https=)
WO (1) WO2009131604A2 (https=)
ZA (1) ZA201005943B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2947149T3 (en) * 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
SG187513A1 (en) 2008-01-24 2013-02-28 Univ Texas Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
EP2900685B1 (en) 2012-09-27 2017-10-25 Research Development Foundation Attenuated chikungunya virus
JP6426695B2 (ja) 2013-03-14 2018-11-21 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 弱毒生アルファウイルス製剤のための組成物および方法
US20190106682A1 (en) * 2016-03-31 2019-04-11 Takeda Vaccines, Inc. Live, Attenuated Alphavirus Constructs and Methods and Uses Thereof
CN109476708B (zh) * 2016-05-27 2023-12-22 格里菲斯大学 针对致关节炎甲病毒的疫苗
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
SG11202005792RA (en) 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
CA3111440A1 (en) * 2018-08-03 2020-02-06 Uab Research Foundation Methods and compositions for alphavirus vaccine
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
WO2021138447A1 (en) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2327189A1 (en) 2000-12-21 2002-06-21 The Minister Of National Defence Novel dna-based vaccine against the encephalitis alphaviruses
US20060251678A1 (en) 2004-09-14 2006-11-09 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
US20070166820A1 (en) * 2003-03-20 2007-07-19 Smith Jonathan F Alphavirus replicons and helper constructs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
CA2533614C (en) 2004-07-30 2011-05-03 Research In Motion Limited Method and system for coordinating device setting between a communications client and its host device
CA2579507C (en) 2006-03-15 2017-06-13 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
SG187513A1 (en) * 2008-01-24 2013-02-28 Univ Texas Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2327189A1 (en) 2000-12-21 2002-06-21 The Minister Of National Defence Novel dna-based vaccine against the encephalitis alphaviruses
US20070166820A1 (en) * 2003-03-20 2007-07-19 Smith Jonathan F Alphavirus replicons and helper constructs
US20060251678A1 (en) 2004-09-14 2006-11-09 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Virology. 2001, vol. 78, no. 8, pp. 3706-3718.

Also Published As

Publication number Publication date
EP2250269A2 (en) 2010-11-17
EP2250269A4 (en) 2012-01-04
AU2009238667A1 (en) 2009-10-29
MX378503B (es) 2025-03-11
JP5758632B2 (ja) 2015-08-05
JP2011523347A (ja) 2011-08-11
CA2910235C (en) 2021-07-06
US20110052634A1 (en) 2011-03-03
CN102083986B (zh) 2014-06-18
MY178870A (en) 2020-10-21
SG10201606111XA (en) 2016-09-29
KR20100106599A (ko) 2010-10-01
US20170240919A1 (en) 2017-08-24
US8426188B2 (en) 2013-04-23
EP3085787A1 (en) 2016-10-26
EP2250269B1 (en) 2016-03-16
CA2713165C (en) 2015-12-29
IL232032A0 (en) 2014-05-28
NZ603790A (en) 2014-08-29
US10533186B2 (en) 2020-01-14
US20140010841A1 (en) 2014-01-09
KR20160124255A (ko) 2016-10-26
ZA201005943B (en) 2011-04-28
KR101913790B1 (ko) 2018-12-28
CN102083986A (zh) 2011-06-01
MX367792B (es) 2019-09-05
EP3085787B1 (en) 2020-10-28
CA2910235A1 (en) 2009-10-29
US9580690B2 (en) 2017-02-28
IL207167A0 (en) 2010-12-30
CO6290702A2 (es) 2011-06-20
NZ587502A (en) 2012-12-21
CA2713165A1 (en) 2009-10-29
IL207167A (en) 2014-04-30
WO2009131604A2 (en) 2009-10-29
SG187513A1 (en) 2013-02-28
MX2019010530A (es) 2019-10-15
MX2010007989A (es) 2010-12-21
WO2009131604A3 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
KR101668849B1 (ko) 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도
White et al. Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5′ untranslated region
Paessler et al. Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic
Domingo et al. The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance—a review
JP5538729B2 (ja) 偽感染性フラビウイルスおよびそれらの使用
Volkova et al. IRES-dependent replication of Venezuelan equine encephalitis virus makes it highly attenuated and incapable of replicating in mosquito cells
Pandya et al. A vaccine candidate for eastern equine encephalitis virus based on IRES-mediated attenuation
US8343506B2 (en) Chimeric chikungunya virus and uses thereof
Ryman et al. Attenuation of Sindbis virus variants incorporating uncleaved PE2 glycoprotein is correlated with attachment to cell-surface heparan sulfate
US9402890B2 (en) Methods and compositions for pseudoinfectious alphaviruses
AU2018229512B2 (en) Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
AU2014265084B2 (en) Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
HK1230647A1 (en) Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
WO2007002793A2 (en) Chimeric sindbis-eastern equine encephalitis virus and uses thereof
Attenuated Recombinant Sindbis/Venezuelan Equine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20191008

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20211019

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20211019